Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study

被引：0

作者：

le Coutre, Philipp D. ^{[1
]}

Giles, Francis J. ^{[2
,3
]}

Pinilla-Ibarz, Javier ^{[4
]}

Larson, Richard A. ^{[5
]}

Gattermann, Norbert ^{[6
]}

Ottmann, Oliver G. ^{[7
]}

Hochhaus, Andreas ^{[8
]}

Radich, Jerald P. ^{[9
]}

Saglio, Giuseppe ^{[10
]}

Hughes, Timothy P. ^{[11
]}

Martinelli, Giovanni ^{[12
]}

Kim, Dong-Wook ^{[13
]}

Branford, Susan ^{[11
]}

Mueller, Martin C. ^{[14
]}

Shou, Yaping ^{[15
]}

Novick, Steven ^{[16
]}

Fan, Xiaolin ^{[16
]}

Cortes, Jorge E. ^{[17
]}

Baccarani, Michele ^{[12
]}

Kantarjian, Hagop M. ^{[17
]}

机构：

[1] Charite, D-13353 Berlin, Germany

[2] Natl Univ Ireland Galway, Galway, Ireland

[3] Trinity Coll Dublin, Galway, Ireland

[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Univ Dusseldorf, D-40225 Dusseldorf, Germany

[7] Univ Klin Frankfurt, Med Klin 2, MRD Lab, Frankfurt, Germany

[8] Univ Klinikum Jena, Jena, Germany

[9] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[10] Univ Turin, Orbassano, Italy

[11] Royal Adelaide Hosp, SA Pathol, Adelaide, SA 5000, Australia

[12] Univ Bologna, Bologna, Italy

[13] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[14] Univ Heidelberg, Med Klin 3, Med Fak Mannheim, D-6800 Mannheim, Germany

[15] Novartis Inst BioMed Res, Cambridge, MA USA

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1610 / 1610

页数：1

共 50 条

[21] BUDGET IMPACT ANALYSIS OF DASATINIB IN IMATINIB-RESISTANT OR-INTOLERANT PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) IN THE CHINESE SETTING
Wu, B.
VALUE IN HEALTH, 2016, 19 (07) : A881 - A881
[22] Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Hochhaus, Andreas
Kim, Dong-Wook
Martinelli, Giovanni
Hughes, Timothy P.
Soverini, Simona
Branford, Susan
Muller, Martin C.
Erben, Philipp
Haque, Ariful
Shou, Yaping
Saglio, Giuseppe
Radich, Jerald P.
BLOOD, 2008, 112 (11) : 1103 - 1104
[23] SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB
Rea, D.
Vellenga, E.
Junghanss, C.
Baccarani, M.
Kantarjian, H.
Lofgren, C.
Dejardin, D.
Hochhaus, A.
HAEMATOLOGICA, 2012, 97 : 80 - 80
[24] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
Rosti, G.
le Coutre, P.
Bhalla, K.
Giles, F.
Ossenkoppele, G.
Hochhaus, A.
Gattermann, N.
Haque, A.
Weitzman, A.
Baccarani, M.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[25] A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP).
le Coutre, Philipp
Bhalla, Kapil
Giles, Francis
Baccarani, Michele
Ossenkoppele, Gert J.
Hochhaus, Andreas
Gattermann, Norbert
Rafferty, Teresa
Haque, Ariful
Weitzman, Aaron
Kantarjian, Hagop
BLOOD, 2006, 108 (11) : 53A - 53A
[26] Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Branford, Susan
Kim, Dong-Wook
Soverini, Simona
Gottardi, Enrico
Beppu, Lan
Mueller, Martin C.
Haque, Ariful
Shou, Yaping
Woodman, Richard C.
Kantarjian, Hagop M.
Martinelli, Giovanni
Radich, Jerald P.
Saglio, Giuseppe
Hughes, Timothy P.
Hochhaus, Andreas
BLOOD, 2009, 114 (22) : 1275 - 1276
[27] Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
Jabbour, Elias
Kantarjian, Hagop M.
Baccarani, Michele
de Coutre, Philipp D.
Haque, Ariful
Gallagher, Neil J.
Cortes, Jorge
Giles, Francis
BLOOD, 2008, 112 (11) : 1103 - 1103
[28] Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study
Gambacorti-Passerini, Carlo
Khoury, H. Jean
Kantarjian, Hagop M.
Lipton, Jeffrey H.
Kim, Dong-Wook
Schafhausen, Philippe
Matczak, Ewa M.
Leip, Eric
Noonan, Kay
Bruemmendorf, Tim H.
Cortes, Jorge E.
BLOOD, 2014, 124 (21)
[29] RAPID INITIAL DECLINE IN BCR-ABL LEVELS IS ASSOCIATED WITH SUPERIOR RESPONSES IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB
Stein, A.
Shou, Y.
Bottino, D.
Chia, Y. L.
Woodman, R.
Martinelli, G.
Hughes, T.
Mueller, M.
Beppu, L.
Gottardi, E.
Branford, S.
Soverini, S.
Goh, H.
Hochhaus, A.
Kim, D.
Saglio, G.
Radich, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 56 - 56
[30] ENESTND 5-YEAR FOLLOW-UP: CONTINUED BENEFIT OF FRONTLINE NILOTINIB (NIL) COMPARED WITH IMATINIB (IM) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
Hughes, T. P.
le Coutre, P. D.
Jootar, S.
Reiffers, J.
Turkina, A. G.
Saglio, G.
Hochhaus, A.
Kantarjian, H. M.
Kemp, C.
Deng, W.
Menssen, H. D.
Larson, R. A.
HAEMATOLOGICA, 2014, 99 : 236 - 237

← 1 2 3 4 5 →